Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases.
BACKGROUND
Qualitative and quantitative changes in IGRA response offer promise as biomarkers to monitor Tuberculosis (TB) drug therapy, and for the comparison of new interventions. We studied the decay kinetics of TB-specific antigen T-cell responses measured with an in-house ELISPOT assay during the course of therapy.


METHODS
Newly diagnosed sputum smear positive TB cases with typical TB chest radiographs were recruited. All patients were given standard anti-TB treatment. Each subject was followed up for 6 months and treatment outcomes were documented. Blood samples were obtained for the ESAT-6 and CFP-10 (EC) ELISPOT at diagnosis, 1-, 2-, 4- and 6-months. Qualitative and quantitative reversion of the ELISPOT results were assessed with McNemar test, conditional logistic regression and mixed-effects hierarchical Poisson models.


RESULTS
A total of 116 cases were recruited and EC ELISPOT was positive for 87% (95 of 109) at recruitment. There was a significant decrease in the proportion of EC ELISPOT positive cases over the treatment period (p<0.001). Most of the reversion occurred between the start and first month of treatment and at completion at 6 months. ESAT-6 had higher median counts compared to CFP-10 at all time points. Counts for each antigen declined significantly with therapy (p<0.001). Reverters had lower median SFUs at the start of treatment compared to non-Reverters for both antigens. Apart from the higher median counts for non-Reverters, no other risk factors for non-reversion were found.


CONCLUSIONS
TB treatment induces qualitative and quantitative reversion of a positive in-house IGRA in newly diagnosed cases of active TB disease. As this does not occur reliably in the majority of cured individuals, qualitative and quantitative reversion of an IGRA ELISPOT has limited clinical utility as a surrogate marker of treatment efficacy.
Adetifa
Ifedayo M O
IM
Bacterial Diseases Programme, Medical Research Council (United Kingdom) Laboratories, Fajara, The Gambia. iadetifa@mrc.gm
Ota
Martin O C
MO
Walther
Brigitte
B
Hammond
Abdulrahman S
AS
Lugos
Moses D
MD
Jeffries
David J
DJ
Donkor
Simon A
SA
Adegbola
Richard A
RA
Hill
Philip C
PC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014376:Tuberculosis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D055815:Young Adult
D000995:Antitubercular Agents; D007371:Interferon-gamma
BMC Infect Dis. 2010 May 27;10:138
20507549
AIDS. 2010 Jan 28;24(3):417-26
20042847
Immunol Invest. 2009;38(5):341-9
19811412
Diagn Microbiol Infect Dis. 2009 Jan;63(1):43-51
19026511
Pediatr Infect Dis J. 2010 May;29(5):439-43
20068506
J Infect. 2007 Aug;55(2):169-73
17448540
J Exp Med. 1997 Sep 15;186(6):859-65
9294140
Clin Infect Dis. 2005 Jan 15;40(2):273-8
15655747
Respir Med. 2009 Jan;103(1):30-4
18977647
Am J Respir Crit Care Med. 2007 Feb 1;175(3):282-7
17082492
BMC Infect Dis. 2009 Feb 28;9:23
19250549
PLoS One. 2009;4(4):e5187
19365543
PLoS One. 2009;4(1):e4130
19125189
Pediatr Infect Dis J. 2010 Mar;29(3):285-6
20190616
Nat Rev Immunol. 2002 Apr;2(4):251-62
12001996
J Clin Microbiol. 2002 Feb;40(2):704-6
11826002
J Infect. 2009 Mar;58(3):197-204
18848730
Curr Opin Pulm Med. 2009 May;15(3):188-200
19387262
Int J Tuberc Lung Dis. 2006 Feb;10(2):192-8
16499260
Pediatrics. 2006 May;117(5):1542-8
16651307
Eur Respir J. 2010 Aug;36(2):355-61
19926734
J Infect Dis. 2006 Feb 1;193(3):354-9
16388482
BMC Infect Dis. 2006 Mar 30;6:66
16573826
Infect Immun. 2002 Jun;70(6):3026-32
12010994
BMC Infect Dis. 2008 Jan 28;8:11
18226199
Respir Res. 2007 Jan 27;8:5
17257436
PLoS One. 2008 Jan 02;3(1):e1379
18167540
Int J Tuberc Lung Dis. 2010 Jul;14(7):909-15
20550777
Nat Rev Immunol. 2002 Apr;2(4):263-72
12001997
Ann Intern Med. 2007 Mar 6;146(5):340-54
17339619
Int J Tuberc Lung Dis. 2003 Apr;7(4):390-3
12729346
Clin Infect Dis. 2004 Apr 1;38(7):966-73
15034828
Clin Infect Dis. 2005 May 1;40(9):1301-8
15825033
Clin Infect Dis. 2004 Mar 1;38(5):754-6
14986262
J Occup Med Toxicol. 2006 May 23;1:7
16722616
Int J Tuberc Lung Dis. 2007 Mar;11(3):350-2
17352104
BMC Infect Dis. 2007 Oct 25;7:122
17961228
Nat Immunol. 2001 May;2(5):415-22
11323695